Boston Scientific Corporation

NYSE:BSX Stock Report

Market Cap: US$111.1b

Boston Scientific Management

Management criteria checks 3/4

Boston Scientific's CEO is Mike Mahoney, appointed in Oct 2011, has a tenure of 12.75 years. total yearly compensation is $18.72M, comprised of 7.5% salary and 92.5% bonuses, including company stock and options. directly owns 0.13% of the company’s shares, worth $144.75M. The average tenure of the management team and the board of directors is 8.3 years and 8.1 years respectively.

Key information

Mike Mahoney

Chief executive officer

US$18.7m

Total compensation

CEO salary percentage7.5%
CEO tenure12.8yrs
CEO ownership0.1%
Management average tenure8.3yrs
Board average tenure8.1yrs

Recent management updates

Recent updates

Boston Scientific Q2 Earnings Preview: Can The Rally Continue?

Jul 17

Here's Why We Think Boston Scientific (NYSE:BSX) Is Well Worth Watching

Jul 05
Here's Why We Think Boston Scientific (NYSE:BSX) Is Well Worth Watching

Should You Investigate Boston Scientific Corporation (NYSE:BSX) At US$77.00?

Jun 21
Should You Investigate Boston Scientific Corporation (NYSE:BSX) At US$77.00?

Boston Scientific Has Become A Standout Growth Story In Med-Tech

Jun 13

Why We're Not Concerned About Boston Scientific Corporation's (NYSE:BSX) Share Price

Jun 08
Why We're Not Concerned About Boston Scientific Corporation's (NYSE:BSX) Share Price

Is Boston Scientific (NYSE:BSX) Using Too Much Debt?

May 10
Is Boston Scientific (NYSE:BSX) Using Too Much Debt?

Boston Scientific (NYSE:BSX) Is Reinvesting At Lower Rates Of Return

Apr 22
Boston Scientific (NYSE:BSX) Is Reinvesting At Lower Rates Of Return

Boston Scientific: Implications Of The Axonics-Medtronic Patent Clash

Apr 05

A Look At The Fair Value Of Boston Scientific Corporation (NYSE:BSX)

Mar 26
A Look At The Fair Value Of Boston Scientific Corporation (NYSE:BSX)

We Ran A Stock Scan For Earnings Growth And Boston Scientific (NYSE:BSX) Passed With Ease

Feb 29
We Ran A Stock Scan For Earnings Growth And Boston Scientific (NYSE:BSX) Passed With Ease

What You Can Learn From Boston Scientific Corporation's (NYSE:BSX) P/E

Feb 15
What You Can Learn From Boston Scientific Corporation's (NYSE:BSX) P/E

Is Boston Scientific (NYSE:BSX) A Risky Investment?

Feb 02
Is Boston Scientific (NYSE:BSX) A Risky Investment?

Boston Scientific (NYSE:BSX) Could Be Struggling To Allocate Capital

Jan 19
Boston Scientific (NYSE:BSX) Could Be Struggling To Allocate Capital

Boston Scientific: Portfolio Updates Driving Top-Line Growth

Jan 17

Boston Scientific: Continued M&A Drives More Growth

Jan 10

Is Boston Scientific Corporation (NYSE:BSX) Worth US$56.1 Based On Its Intrinsic Value?

Dec 04
Is Boston Scientific Corporation (NYSE:BSX) Worth US$56.1 Based On Its Intrinsic Value?

Does Boston Scientific (NYSE:BSX) Have A Healthy Balance Sheet?

Nov 03
Does Boston Scientific (NYSE:BSX) Have A Healthy Balance Sheet?

Boston Scientific: Delivering Strong Growth, But Sector Derating Is A Big Issue

Oct 30

ADVENT Offers Up An Early Present For Boston Scientific Investors

Aug 28

Estimating The Fair Value Of Boston Scientific Corporation (NYSE:BSX)

Aug 24
Estimating The Fair Value Of Boston Scientific Corporation (NYSE:BSX)

Boston Scientific (NYSE:BSX) Seems To Use Debt Quite Sensibly

Jul 25
Boston Scientific (NYSE:BSX) Seems To Use Debt Quite Sensibly

Boston Scientific Remains Operationally Sound But May Have Limited Upside

Jul 14

Investors Could Be Concerned With Boston Scientific's (NYSE:BSX) Returns On Capital

Jul 10
Investors Could Be Concerned With Boston Scientific's (NYSE:BSX) Returns On Capital

Boston Scientific Corporation (NYSE:BSX) Shares Could Be 29% Above Their Intrinsic Value Estimate

May 21
Boston Scientific Corporation (NYSE:BSX) Shares Could Be 29% Above Their Intrinsic Value Estimate

Here's Why Boston Scientific (NYSE:BSX) Can Manage Its Debt Responsibly

Apr 18
Here's Why Boston Scientific (NYSE:BSX) Can Manage Its Debt Responsibly

Returns On Capital At Boston Scientific (NYSE:BSX) Paint A Concerning Picture

Apr 03
Returns On Capital At Boston Scientific (NYSE:BSX) Paint A Concerning Picture

Boston Scientific Stands Out With Strong, Diversified Growth Profile

Feb 15

Boston Scientific Non-GAAP EPS of $0.45 misses by $0.02, revenue of $3.24B in-line

Feb 01

Boston Scientific sees double digit EPS growth in 2023 - JPMorgan Healthcare conference

Jan 11

CEO Compensation Analysis

How has Mike Mahoney's remuneration changed compared to Boston Scientific's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2024n/an/a

US$2b

Dec 31 2023US$19mUS$1m

US$2b

Sep 30 2023n/an/a

US$1b

Jun 30 2023n/an/a

US$861m

Mar 31 2023n/an/a

US$846m

Dec 31 2022US$17mUS$1m

US$642m

Sep 30 2022n/an/a

US$596m

Jun 30 2022n/an/a

US$828m

Mar 31 2022n/an/a

US$754m

Dec 31 2021US$16mUS$1m

US$985m

Sep 30 2021n/an/a

US$1b

Jun 30 2021n/an/a

US$526m

Mar 31 2021n/an/a

US$201m

Dec 31 2020US$14mUS$667k

-US$115m

Sep 30 2020n/an/a

US$4b

Jun 30 2020n/an/a

US$4b

Mar 31 2020n/an/a

US$4b

Dec 31 2019US$16mUS$1m

US$5b

Sep 30 2019n/an/a

US$1b

Jun 30 2019n/an/a

US$1b

Mar 31 2019n/an/a

US$2b

Dec 31 2018US$14mUS$1m

US$2b

Sep 30 2018n/an/a

US$670m

Jun 30 2018n/an/a

US$521m

Mar 31 2018n/an/a

US$112m

Dec 31 2017US$13mUS$1m

US$104m

Compensation vs Market: Mike's total compensation ($USD18.72M) is above average for companies of similar size in the US market ($USD13.25M).

Compensation vs Earnings: Mike's compensation has been consistent with company performance over the past year.


CEO

Mike Mahoney (59 yo)

12.8yrs

Tenure

US$18,723,735

Compensation

Mr. Michael F. Mahoney, also known as Mike, has been Independent Director of CVS Health Corporation since November 01, 2023. He has been Chairman of Boston Scientific Corporation since May 3, 2016, and is...


Leadership Team

NamePositionTenureCompensationOwnership
Michael Mahoney
Chairman12.8yrsUS$18.72m0.13%
$ 144.7m
Daniel Brennan
Executive VP & CFO10.5yrsUS$5.83m0.015%
$ 16.9m
Joseph Fitzgerald
Executive VP & Group President of Cardiology14.4yrsUS$5.59m0.013%
$ 14.8m
Jeffrey Mirviss
Executive VP & President of Peripheral Interventions11.5yrsUS$3.78m0.0019%
$ 2.1m
Arthur Crosswell Butcher
Executive VP and Group President of MedSurg & Asia Pacific8yrsUS$4.27m0.0015%
$ 1.7m
John Sorenson
Executive Vice President of Global Operations2.2yrsno data0.0036%
$ 4.0m
Emily Woodworth
Senior VPless than a yearno data0.00026%
$ 288.8k
Jodi Eddy
Senior VP and Chief Information & Digital Officer8.6yrsno datano data
Jonathan Monson
Senior VP of Investor Relationsless than a yearno data0.0026%
$ 2.9m
Vance Brown
Senior VP3.1yrsno data0.0023%
$ 2.6m
Mary Moynihan
Senior VP of Market Access & Chief Marketing Officer3.2yrsno datano data
Wendy Carruthers
Executive Vice President of Human Resources11.6yrsno data0.0029%
$ 3.2m

8.3yrs

Average Tenure

56yo

Average Age

Experienced Management: BSX's management team is seasoned and experienced (8.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Michael Mahoney
Chairman11.7yrsUS$18.72m0.13%
$ 144.7m
Edward Ludwig
Lead Independent Director10.3yrsUS$360.00k0.0030%
$ 3.3m
Ellen Zane
Independent Director8.3yrsUS$335.00k0.0033%
$ 3.7m
Yoshiaki Fujimori
Independent Director8yrsUS$320.00k0.00020%
$ 222.1k
David Wichmann
Independent Director3.1yrsUS$338.75k0.0027%
$ 3.0m
Cheryl Pegus
Directorless than a yearno datano data
Charles Dockendorff
Independent Director9.3yrsUS$326.25k0.0043%
$ 4.8m
John Sununu
Independent Director15.3yrsUS$340.00k0.0036%
$ 4.0m
Jessica Mega
Independent Director1.1yrsUS$233.23k0.00042%
$ 466.5k
Susan Morano
Independent Director1.1yrsUS$233.23k0.00027%
$ 299.9k

8.1yrs

Average Tenure

61yo

Average Age

Experienced Board: BSX's board of directors are considered experienced (8.1 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.